Programming cytomegalovirus as an HIV vaccine.
Trends Immunol
; 44(4): 287-304, 2023 04.
Article
en En
| MEDLINE
| ID: mdl-36894436
ABSTRACT
The initial development of cytomegalovirus (CMV) as a vaccine vector for HIV/simian immunodeficiency virus (SIV) was predicated on its potential to pre-position high-frequency, effector-differentiated, CD8+ T cells in tissues for immediate immune interception of nascent primary infection. This goal was achieved and also led to the unexpected discoveries that non-human primate (NHP) CMVs can be programmed to differentially elicit CD8+ T cell responses that recognize viral peptides via classical MHC-Ia, and/or MHC-II, and/or MHC-E, and that MHC-E-restricted CD8+ T cell responses can uniquely mediate stringent arrest and subsequent clearance of highly pathogenic SIV, an unprecedented type of vaccine-mediated protection. These discoveries delineate CMV vector-elicited MHC-E-restricted CD8+ T cells as a functionally distinct T cell response with the potential for superior efficacy against HIV-1, and possibly other infectious agents or cancers.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Síndrome de Inmunodeficiencia Adquirida del Simio
/
Virus de la Inmunodeficiencia de los Simios
/
Vacunas contra el SIDA
/
Infecciones por Citomegalovirus
Límite:
Animals
Idioma:
En
Año:
2023
Tipo del documento:
Article